208 related articles for article (PubMed ID: 19468065)
1. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum.
Kawakami Y; Tomimori Y; Yumoto K; Hasegawa S; Ando T; Tagaya Y; Crotty S; Kawakami T
J Exp Med; 2009 Jun; 206(6):1219-25. PubMed ID: 19468065
[TBL] [Abstract][Full Text] [Related]
2. IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of Vaccinia virus in a mouse model of eczema vaccinatum.
Darling AR; Freyschmidt EJ; Burton OT; Koleoglou KJ; Oyoshi MK; Oettgen HC
Clin Immunol; 2014 Feb; 150(2):153-60. PubMed ID: 24412909
[TBL] [Abstract][Full Text] [Related]
3. Filaggrin deficiency promotes the dissemination of cutaneously inoculated vaccinia virus.
Oyoshi MK; Beaupré J; Venturelli N; Lewis CN; Iwakura Y; Geha RS
J Allergy Clin Immunol; 2015 Jun; 135(6):1511-8.e6. PubMed ID: 25649082
[TBL] [Abstract][Full Text] [Related]
4. Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models.
Achdout H; Lustig S; Israely T; Erez N; Politi B; Tamir H; Israeli O; Waner T; Melamed S; Paran N
Vaccine; 2017 Jul; 35(33):4245-4254. PubMed ID: 28625523
[TBL] [Abstract][Full Text] [Related]
5. Protective murine and human monoclonal antibodies against eczema vaccinatum.
Tomimori Y; Kawakami Y; McCausland MM; Ando T; Koriazova L; Kato S; Kawakami T; Crotty S
Antivir Ther; 2011; 16(1):67-75. PubMed ID: 21311110
[TBL] [Abstract][Full Text] [Related]
6. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.
Knitlova J; Hajkova V; Voska L; Elsterova J; Obrova B; Melkova Z
PLoS One; 2014; 9(12):e114374. PubMed ID: 25486419
[TBL] [Abstract][Full Text] [Related]
7. Defective natural killer cell activity in a mouse model of eczema herpeticum.
Kawakami Y; Ando T; Lee JR; Kim G; Kawakami Y; Nakasaki T; Nakasaki M; Matsumoto K; Choi YS; Kawakami T
J Allergy Clin Immunol; 2017 Mar; 139(3):997-1006.e10. PubMed ID: 27476888
[TBL] [Abstract][Full Text] [Related]
8. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation.
Scott JE; ElKhal A; Freyschmidt EJ; MacArthur DH; McDonald D; Howell MD; Leung DY; Laouar A; Manjunath N; Bianchi T; Boes M; Oettgen HC; Geha RS
J Allergy Clin Immunol; 2007 Dec; 120(6):1382-8. PubMed ID: 17889291
[TBL] [Abstract][Full Text] [Related]
9. IL-1R Type 1-Deficient Mice Demonstrate an Impaired Host Immune Response against Cutaneous Vaccinia Virus Infection.
Tian T; Jin MQ; Dubin K; King SL; Hoetzenecker W; Murphy GF; Chen CA; Kupper TS; Fuhlbrigge RC
J Immunol; 2017 Jun; 198(11):4341-4351. PubMed ID: 28468973
[TBL] [Abstract][Full Text] [Related]
10. Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response.
Oyoshi MK; Elkhal A; Kumar L; Scott JE; Koduru S; He R; Leung DY; Howell MD; Oettgen HC; Murphy GF; Geha RS
Proc Natl Acad Sci U S A; 2009 Sep; 106(35):14954-9. PubMed ID: 19706451
[TBL] [Abstract][Full Text] [Related]
11. Thymic stromal lymphopoietin and IL-33 promote skin inflammation and vaccinia virus replication in a mouse model of atopic dermatitis.
Oyoshi MK; Venturelli N; Geha RS
J Allergy Clin Immunol; 2016 Jul; 138(1):283-286. PubMed ID: 26830114
[No Abstract] [Full Text] [Related]
12. Immunization with modified vaccinia virus Ankara prevents eczema vaccinatum in a murine model of atopic dermatitis.
Oyoshi MK; Wang JY; Geha RS
J Allergy Clin Immunol; 2011 Oct; 128(4):890-892.e3. PubMed ID: 21820712
[TBL] [Abstract][Full Text] [Related]
13. Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses.
Freyschmidt EJ; Mathias CB; Diaz N; MacArthur DH; Laouar A; Manjunath N; Hofer MD; Wurbel MA; Campbell JJ; Chatila TA; Oettgen HC
J Immunol; 2010 Jul; 185(2):1295-302. PubMed ID: 20548030
[TBL] [Abstract][Full Text] [Related]
14. Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus.
Freyschmidt EJ; Mathias CB; MacArthur DH; Laouar A; Narasimhaswamy M; Weih F; Oettgen HC
J Allergy Clin Immunol; 2007 Mar; 119(3):671-9. PubMed ID: 17336617
[TBL] [Abstract][Full Text] [Related]
15. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum.
Howell MD; Jones JF; Kisich KO; Streib JE; Gallo RL; Leung DY
J Immunol; 2004 Feb; 172(3):1763-7. PubMed ID: 14734759
[TBL] [Abstract][Full Text] [Related]
16. Vaccinia Ig ameliorates eczema vaccinatum in a murine model of atopic dermatitis.
Oyoshi MK; Ramesh N; Geha RS
J Invest Dermatol; 2012 Apr; 132(4):1299-301. PubMed ID: 22189790
[No Abstract] [Full Text] [Related]
17. Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.
Domenico J; Lucas JJ; Fujita M; Gelfand EW
Int Arch Allergy Immunol; 2012; 158(2):196-205. PubMed ID: 22286752
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ;
MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832
[TBL] [Abstract][Full Text] [Related]
19. Eczema vaccinatum.
Reed JL; Scott DE; Bray M
Clin Infect Dis; 2012 Mar; 54(6):832-40. PubMed ID: 22291103
[TBL] [Abstract][Full Text] [Related]
20. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus.
Howell MD; Gallo RL; Boguniewicz M; Jones JF; Wong C; Streib JE; Leung DY
Immunity; 2006 Mar; 24(3):341-8. PubMed ID: 16546102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
